Resumo

SHEN, Xiaodong et al. Dihydroartemisinin, an artemisinin derivative, reverses oxaliplatin resistance in human colorectal cancer cells by regulating the SIRT3/PI3K/AKT signalling pathway. Invest. clín [online]. 2024, vol.65, n.3, pp.267-278.  Epub 12-Set-2024. ISSN 2477-9393.  https://doi.org/10.54817/ic.v65n3a01.

Dihydroartemisinin (DHA), a derivative of artemisinin, has been shown to act as a chemosensitizer of various cancer chemotherapeutic agents both in vitro and in vivo. However, in colorectal cancer (CRC), no study has focused on the effect of DHA on oxaliplatin (L -OHP) resistance. Our study aimed to examine the effectiveness of DHA in reversing the resistance of human CRC cells to L -OHP, as well as its underlying molecular mechanisms. LoVo cells were purchased from ATCC, while LoVo/L -OHP cells were obtained by exposing LoVo cells to progressively increasing concentrations of L -OHP. LoVo/L -OHP were treated with various concentrations of DHA, and cell apoptosis ratio and viability were assessed by flow cytometry and CCK-8. Our results showed that DHA treatment remarkably decreased the viability of LoVo/L -OHP cells and increased the apoptosis ratio. As the mechanism of action, we found that DHA enhanced the expression of Sirtuin 3 (SIRT3) and suppressed the phosphatidylinositol 3-kinase (PI3K)/AKT signalling cascade. Silencing of SIRT3 reversed the effect of DHA on cell apoptosis and viability by activating the PI3K/AKT axis in LoVo/L -OHP cells. Overall, our study found that DHA has the ability to counteract L -OHP resistance in LoVo/L -OHP cells through the modulation of the SIRT3/PI3K/AKT signalling pathway, suggesting a new research target for CRC treatment.

Palavras-chave : dihydroartemisinin; SIRT3; oxaliplatin; colorectal cancer.

        · resumo em Espanhol     · texto em Inglês     · Inglês ( pdf )